We examined direct effects of GLP-1 analogues on abdominal AT depots, which are prone to expand with increasing obesity and susceptible to AT dysfunction.15 Our study shows that acute treatments based on GLP-1 analogues may have an advantage by increasing adiponectin expression and that they reduce elastin secretion by which they take part in ECM remodelling. Here, GLP1R is linked to obesity disorder.